Rallybio

Rallybio FCF/Debt

The Free Cash Flow to Debt Ratio of Rallybio (RLYB) as of Nov 3, 2026 is -16,939.20 %. In the previous year, Free Cash Flow to Debt Ratio was -32,001.30 % — a change of -47.07% (higher).

FCF/Debt

-16,939.20 %

YoY

-47.07%

Last updated:

Free Cash Flow to Debt Ratio of Rallybio is 2025 -16,939.20 % . Free Cash Flow to Debt Ratio of Rallybio was 2024 -32,001.30 % . It decreases by -47.07% higher compared to the previous year.

The Rallybio FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2022
-10,331.17 USD
Jan 1, 2023
-15,376.79 USD
Jan 1, 2024
-32,001.30 USD
Jan 1, 2025
-16,939.20 USD
The Rallybio FCF/Debt history
YEARFCF/DebtYoY
-16,939.20 %-47.07%
-32,001.30 %+108.11%
-15,376.79 %+48.84%
-10,331.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rallybio Stock analysis

What does Rallybio do? Rallybio Corp. generates revenue by identifying, researching, and developing clinical biotechnology products and therapies for severe and rare diseases. The firm focuses on accelerating the development of life-transforming therapies, with a specific program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease affecting fetuses and newborns. The company's pipeline includes several candidates such as RLYB212, a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing HPA-1a maternal alloimmunization and FNAIT occurrence. Additionally, the advanced product candidate RLYB116 serves as an inhibitor of complement component 5 (C5) to treat complement dysregulation conditions including paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The pipeline also features RLYB114, a pegylated C5-targeted Affibody molecule, and the ENPP1 Program, alongside RLYB331, targeting patients with these specific medical needs. Rallybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rallybio stock

Free Cash Flow to Debt Ratio of Rallybio is -16,939.20 % in 2025.

Free Cash Flow to Debt Ratio of Rallybio changed from -32,001.30 % to -16,939.20 %, representing a -47.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Rallybio since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Rallybio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rallybio

All Key Metrics — Rallybio